Glenmark Pharmaceuticals Limited Share Price and Company Fundamentals
Last traded: Last Friday at 10:00 AM
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Key Metrics
PE ratio
45.95
PB ratio
5.95
Dividend yield
0.23%
Beta
0.26
Market cap
₹625.07B
Enterprise value
₹618.16B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Website | https://glenmarkpharma.com |
| Mailing address | Glenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India |
| Phone / Fax | 91 22 4018 9999 / 91 22 4018 9986 |
Dividends
Dividend yield
0.23%
Dividend amount
₹5.00
Payout ratio
10.36%
5Y Avg. yield
-%
Glenmark Pharmaceuticals Limited paid ₹5.00 dividend and the ex-dividend date was 03 Oct 2025.The dividend payout ratio is 10.36%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GLENMARK dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Jul 2026, following are the company executives and directors listed on Glenmark Pharmaceuticals Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Glenn Mario Saldanha | Chairman, MD & CEO | 55 | |
| Ms. Cherylann Maria Pinto B.Pharm | Executive Director of Corporate Services & Executive Director | 58 | |
| Mr. Alind Sharma | President and Chief Human Resources Officer | 54 | |
| Mr. Ulhas R. Dhuppad | President & Head of Global Pharmaceutical Development | 58 | |
| Mr. Indrajit Bose | President & Chief Quality Officer | ||
| Mr. Brijlal Motwani | President & Chief Quality Officer | ||
| Mr. Alok Malik | President & Business Head of India Formulations | ||
| Mr. Christoph Stoller | President and Business Head of Europe & Emerging Markets | ||
| Mr. Marc T. Kikuchi B.A., M.B.A. | President & Business Head of North America | 55 | |
| Mr. Anurag Mantri | Global CFO & Executive Director | 54 |
Profitability and management effectiveness
Profit margin
8.02%
Operating margin
16.30%
Return on assets
13.90%
Return on equity
14.07%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Glenmark Pharmaceuticals Limited is 625.07B and its enterprise value is 618.16B. The enterprise value to revenue ratio of GLENMARK is 3.64. The enterprise value to EBITDA ratio of GLENMARK is 13.52.
The GLENMARK's stocks Beta value is 0.26 making it 74% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Frequently Asked Questions
1. What is Glenmark Pharmaceuticals Limited's Stock Symbol?
Glenmark Pharmaceuticals Limited trades on NSE under the ticker symbol "GLENMARK".
2. What is Glenmark Pharmaceuticals Limited's stock price today?
One share of GLENMARK stock can currently be purchased for approximately ₹2215.
3. How can I contact Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited's mailing address is Glenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India. The company can be reached via phone at 91 22 4018 9999.
4. What is Glenmark Pharmaceuticals Limited's official website?
The official website of Glenmark Pharmaceuticals Limited is https://glenmarkpharma.com.